Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • MSF to oppose Pfizer's...

    MSF to oppose Pfizer's bid for pneumonia vaccine patent

    Written by savita thakur thakur Published On 2016-07-30T12:23:15+05:30  |  Updated On 30 July 2016 12:23 PM IST
    MSF to oppose Pfizers bid for pneumonia vaccine patent

    New Delhi : Medecins Sans Frontieres (MSF) said it will defend the rights of millions of children around the world to be protected against pneumonia, and will oppose US pharma giant Pfizer's bid for a patent on the pneumococcal conjugate vaccine (PCV13) at a hearing in India's patent office.


    The international humanitarian-aid organisation, also called Doctors Without Borders, filed a "patent opposition" to prevent the US pharmaceutical giant from getting a patent on PCV13, a MSF statement said.


    "The pneumonia vaccine is the world's best-selling vaccine, and last year alone, Pfizer brought in more than $6 billion dollars in sales just for this product meanwhile many developing countries, where millions of children risk getting pneumonia, simply can't afford it," said Greg Elder, Medical Coordinator for MSF's Access Campaign.


    "To make sure children everywhere can be protected from deadly pneumonia, other companies need to be allowed to enter the market so they can supply this vaccine for a much lower price than what Pfizer charges," Elder added.


    Pfizer has priced the pneumonia vaccine, which it markets as Prevenar 13, out of reach of many developing countries and humanitarian organisations.


    According to a 2015 MSF report, at the lowest global price it is now 68 times more expensive to fully vaccinate a child than in 2001, with the pneumonia vaccine accounting for almost half of the price of vaccination of a child in the poorest countries.


    One vaccine producer in India has already announced that it could supply the pneumonia vaccine for $6 per child (for all three doses) to public health programmes and humanitarian organisations like MSF.


    This is almost half the current lowest global price of $10 dollars per child, which is only available to a limited number of developing countries via donor funding through Gavi, the Vaccine Alliance.


    Pneumonia is the leading cause of childhood death, killing almost one million children each year. Currently, pharmaceutical companies Pfizer and GlaxoSmithKline (GSK) are the only two manufacturers of the vaccine, which could prevent a large number of these deaths.

    GlaxoSmithKlineGreg ElderGSKMédecins Sans FrontièresMSFpatentPCV13Pfizerpneumococcal conjugate vaccinePneumoniapneumonia vaccine
    Source : IANS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok